ENALAPRIL MALEATE

Post-LOE

enalapril maleate

Aurobindo Pharma

ANDAORALSOLUTION2 Generics Approved

Approved

Jan 2024

Lifecycle

Post-LOE

Competitive Pressure

60/100

Data completeness

4/8 — Partial

ENALAPRIL MALEATE (enalapril maleate) by Aurobindo Pharma is mechanism of action enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, symptomatic congestive heart failure, usually in combination with diuretics and 4 more indications. First approved in 2024.

$0.0BPart D

Mechanism of Action

Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates…

Indications (5)

Worked on ENALAPRIL MALEATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.